B
Bull
Bull · 25%SEER
$2.82
Precio del escenario
$1.980
-0.030 (-1.49%)Al cierre
Loading chart…
- High
- 2.019
- Open
- 2.010
- VWAP
- 1.99
- Vol
- 156.09K
- Mkt Cap
- 113.64M
- Low
- 1.980
- Amount
- 311.05K
- EV/EBITDA, TTM
- -1.07
Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
AI analysis of Seer Inc (SEER)
holdSeer Inc is not a good buy right now due to its current price of $1.98 being significantly below the analyst price target of $4, indicating potential upside. However, the stock has a very low RSI of 21.566, suggesting it may be oversold, but the negative sentiment from a recent earnings report showing an EPS of -0.31 raises concerns.
Métricas de valoración
The current forward P/E ratio for Seer Inc (SEER) is 0.00, compared to its 5-year average forward P/E of -4.55.
Alphio AI Price Scenarios for SEER
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SEER
Cronología de eventos
Noticias
8.508-13NewsfilterSeer Shareholders Express Discontent with Management's Performance
8.507-30seekingalphaSeer Shares Rise on Revised Acquisition Proposal
8.507-30GlobenewswireSeer, Inc. Receives Acquisition Proposals
- 8.507-30Newsfilter
Seer, Inc. Receives Acquisition Proposals
- 9.007-28Newsfilter
Seer Inc. Stockholders Re-elect Board Members at Annual Meeting
SEER FAQ — answered by Alphio AI
Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument. It operates in the Technology sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Seer Inc is not a good buy right now due to its current price of $1.98 being significantly below the analyst price target of $4, indicating potential upside. However, the stock has a very low RSI of 21.566, suggesting it may be oversold, but the negative sentiment from a recent earnings report showing an EPS of -0.31 raises concerns.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.